No profile data available.
Cadrenal Therapeutics, Inc. (CVKD) is a healthcare company in the blood vessel treatment pharmaceuticals industry, based in Ponte Vedra, United States, with about 5 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$13.24 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $2.82 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions.
Cadrenal Therapeutics reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$2.82 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood vessel treatment pharmaceuticals) include Tenax Therapeutics, Inc. (TENX), Gossamer Bio, Inc. (GOSS), Grace Therapeutics, Inc. (GRCE), Bioxytran, Inc. (BIXT).